zurück

Tralokinumab (atopic dermatitis)

Subject:

  • Active Substance: Tralokinumab
  • Name: Adtralza®
  • Therapeutic area: Atopic dermatitis
  • Pharmaceutical company: Leo Pharma A/S

Time table:

  • Start: 15.07.2021
  • Final decision by G-BA: 06.01.2022

Final decision:

  • No additional benefit proved